{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:09:29Z","timestamp":1793621369234,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI18C2383"],"award-info":[{"award-number":["HI18C2383"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2017R1D1A1B04035927"],"award-info":[{"award-number":["2017R1D1A1B04035927"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korean government Ministry of Science and ICT","award":["2022R1A2C2011941"],"award-info":[{"award-number":["2022R1A2C2011941"]}]},{"name":"Korean government Ministry of Science and ICT","award":["2022R1C1C2002698"],"award-info":[{"award-number":["2022R1C1C2002698"]}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2022IP0026"],"award-info":[{"award-number":["2022IP0026"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2022IP0028"],"award-info":[{"award-number":["2022IP0028"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2023IP0040"],"award-info":[{"award-number":["2023IP0040"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Fellowship Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recurrence is common in glioblastoma multiforme (GBM) because of the infiltrative, residual cells in the tumor margin. Standard therapy for GBM consists of surgical resection followed by chemotherapy and radiotherapy, but the median survival of GBM patients remains poor (~\u20091.5\u00a0years). For recurrent GBM, anti-angiogenic treatment is one of the common treatment approaches. However, current anti-angiogenic treatment modalities are not satisfactory because of the resistance to anti-angiogenic agents in some patients. Therefore, we sought to identify novel prognostic biomarkers that can predict the therapeutic response to anti-angiogenic agents in patients with recurrent glioblastoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We selected patients with recurrent GBM who were treated with anti-angiogenic agents and classified them into responders and non-responders to anti-angiogenic therapy. Then, we performed proteomic analysis using liquid-chromatography mass spectrometry (LC\u2013MS) with formalin-fixed paraffin-embedded (FFPE) tissues obtained from surgical specimens. We conducted a gene-ontology (GO) analysis based on protein abundance in the responder and non-responder groups. Based on the LC\u2013MS and GO analysis results, we identified potential predictive biomarkers for anti-angiogenic therapy and validated them in recurrent glioblastoma patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the mass spectrometry-based approach, 4957 unique proteins were quantified with high confidence across clinical parameters. Unsupervised clustering analysis highlighted distinct proteomic patterns (n\u2009=\u2009269 proteins) between responders and non-responders. The GO term enrichment analysis revealed a cluster of genes related to immune cell-related pathways (e.g., TMEM173, FADD, CD99) in the responder group, whereas the non-responder group had a high expression of genes related to nuclear replisome (POLD) and damaged DNA binding (ERCC2). Immunohistochemistry of these biomarkers showed that the expression levels of TMEM173 and FADD were significantly associated with the overall survival and progression-free survival of patients with recurrent GBM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The candidate biomarkers identified in our protein analysis may be useful for predicting the clinical response to anti-angiogenic agents in patients with recurred GBM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-03936-8","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T07:03:19Z","timestamp":1675321399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Hanwool","family":"Jeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonho","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayeong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunggon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyeup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Ki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Woo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangjoon","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jeong","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-3917","authenticated-orcid":false,"given":"Seungjoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"issue":"12","key":"3936_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871\u201382.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3936_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1535-6108(03)00089-8","volume":"3","author":"K Pietras","year":"2003","unstructured":"Pietras K, et al. PDGF receptors as cancer drug targets. Cancer Cell. 2003;3(5):439\u201343.","journal-title":"Cancer Cell"},{"issue":"9","key":"3936_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","volume":"16","author":"P Saharinen","year":"2017","unstructured":"Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin\u2013TIE pathway. Nat Rev Drug Discovery. 2017;16(9):635\u201361.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"3936_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrc2806","volume":"10","author":"EB Pasquale","year":"2010","unstructured":"Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10(3):165\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3936_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s12885-019-5678-1","volume":"19","author":"M Cuncannon","year":"2019","unstructured":"Cuncannon M, et al. Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma. BMC Cancer. 2019;19(1):445.","journal-title":"BMC Cancer"},{"issue":"6","key":"3936_CR6","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/annonc\/mdy106","volume":"29","author":"D Gramatzki","year":"2018","unstructured":"Gramatzki D, et al. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol. 2018;29(6):1431\u20136.","journal-title":"Ann Oncol"},{"issue":"8","key":"3936_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"5","key":"3936_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/1078-0432.CCR-16-1968","volume":"23","author":"R Kurzrock","year":"2017","unstructured":"Kurzrock R, Stewart DJ. Exploring the benefit\/risk associated with antiangiogenic agents for the treatment of non-small cell lung cancer patients. Clin Cancer Res. 2017;23(5):1137\u201348.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3936_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/PPO.0000000000000328","volume":"24","author":"K Mody","year":"2018","unstructured":"Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic therapy in colorectal cancer. Cancer J. 2018;24(4):165\u201370.","journal-title":"Cancer J"},{"issue":"4","key":"3936_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10911-006-9005-5","volume":"10","author":"GW Sledge Jr","year":"2005","unstructured":"Sledge GW Jr. VEGF-targeting therapy for breast cancer. J Mammary Gland Biol Neoplasia. 2005;10(4):319\u201323.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"26","key":"3936_CR11","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, et al. A phase 3 trial of Bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396.","journal-title":"N Engl J Med"},{"key":"3936_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/OTT.S8157","volume":"3","author":"LC Harshman","year":"2010","unstructured":"Harshman LC, Srinivas S. The bevacizumab experience in advanced renal cell carcinoma. Onco Targets Ther. 2010;3:179\u201389.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"3936_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11523-017-0518-1","volume":"12","author":"LS Rosen","year":"2017","unstructured":"Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol. 2017;12(5):599\u2013610.","journal-title":"Target Oncol"},{"issue":"10103","key":"3936_CR14","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","volume":"390","author":"KS Tewari","year":"2017","unstructured":"Tewari KS, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (gynecologic oncology group 240). The Lancet. 2017;390(10103):1654\u201363.","journal-title":"The Lancet"},{"issue":"8","key":"3936_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/nbt1323","volume":"25","author":"F Shojaei","year":"2007","unstructured":"Shojaei F, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007;25(8):911\u201320.","journal-title":"Nat Biotechnol"},{"issue":"7325","key":"3936_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nature09624","volume":"468","author":"R Wang","year":"2010","unstructured":"Wang R, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010;468(7325):829\u201333.","journal-title":"Nature"},{"key":"3936_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-4614-1445-2_5","volume":"734","author":"MS Sosa","year":"2013","unstructured":"Sosa MS, et al. Regulation of tumor cell dormancy by tissue microenvironments and autophagy. Adv Exp Med Biol. 2013;734:73\u201389.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"3936_CR18","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/s41467-018-04448-6","volume":"9","author":"BH Diplas","year":"2018","unstructured":"Diplas BH, et al. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nat Commun. 2018;9(1):2087.","journal-title":"Nat Commun"},{"issue":"5","key":"3936_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","volume":"6","author":"M Butler","year":"2020","unstructured":"Butler M, et al. <em>MGMT<\/em> status as a clinical biomarker in glioblastoma. Trends in Cancer. 2020;6(5):380\u201391.","journal-title":"Trends in Cancer"},{"issue":"1","key":"3936_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40164-020-00192-0","volume":"9","author":"H Xu","year":"2020","unstructured":"Xu H, et al. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol. 2020;9(1):36.","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"3936_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.5414\/NP300758","volume":"33","author":"C Haberler","year":"2014","unstructured":"Haberler C, W\u00f6hrer A. Clinical Neuropathology practice news 2\u20132014: ATRX, a new candidate biomarker in gliomas. Clin Neuropathol. 2014;33(2):108\u201311.","journal-title":"Clin Neuropathol"},{"issue":"1","key":"3936_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-021-01305-4","volume":"10","author":"C Jiguet-Jiglaire","year":"2022","unstructured":"Jiguet-Jiglaire C, et al. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta Neuropathol Commun. 2022;10(1):1.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"3936_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40478-021-01163-0","volume":"9","author":"Q Wei","year":"2021","unstructured":"Wei Q, et al. TNF\u03b1 secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy. Acta Neuropathol Commun. 2021;9(1):67.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"3936_CR24","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1038\/s41598-019-39067-8","volume":"9","author":"A Arora","year":"2019","unstructured":"Arora A, et al. Serum biomarkers identification by iTRAQ and verification by MRM: S100A8\/S100A9 levels predict tumor-stroma involvement and prognosis in Glioblastoma. Sci Rep. 2019;9(1):2749.","journal-title":"Sci Rep"},{"issue":"26","key":"3936_CR25","doi-asserted-by":"publisher","first-page":"eaaz6119","DOI":"10.1126\/sciadv.aaz6119","volume":"6","author":"A Thakur","year":"2020","unstructured":"Thakur A, et al. Label-free sensing of exosomal MCT1 and CD147 for tracking metabolic reprogramming and malignant progression in glioma. Sci Adv. 2020;6(26):eaaz6119.","journal-title":"Sci Adv"},{"issue":"1","key":"3936_CR26","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/s41467-019-08480-y","volume":"10","author":"T Daubon","year":"2019","unstructured":"Daubon T, et al. Deciphering the complex role of thrombospondin-1 in glioblastoma development. Nat Commun. 2019;10(1):1146.","journal-title":"Nat Commun"},{"issue":"8","key":"3936_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592\u2013603.","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"3936_CR28","doi-asserted-by":"publisher","first-page":"6616","DOI":"10.1158\/0008-5472.CAN-04-0401","volume":"64","author":"G Bocci","year":"2004","unstructured":"Bocci G, et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 2004;64(18):6616\u201325.","journal-title":"Cancer Res"},{"issue":"43","key":"3936_CR29","doi-asserted-by":"publisher","first-page":"17069","DOI":"10.1073\/pnas.0708148104","volume":"104","author":"JM Ebos","year":"2007","unstructured":"Ebos JM, et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA. 2007;104(43):17069\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3936_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4049\/jimmunol.176.1.284","volume":"176","author":"SK Bunt","year":"2006","unstructured":"Bunt SK, et al. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2006;176(1):284\u201390.","journal-title":"J Immunol"},{"issue":"10","key":"3936_CR31","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso MR, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Investig. 2006;116(10):2610\u201321.","journal-title":"J Clin Investig"},{"issue":"10","key":"3936_CR32","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/S1470-2045(12)70275-9","volume":"13","author":"BP Schneider","year":"2012","unstructured":"Schneider BP, Shen F, Miller KD. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol. 2012;13(10):e427\u201336.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3936_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12943-018-0766-4","volume":"17","author":"Y Wang","year":"2018","unstructured":"Wang Y, et al. New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications. Mol Cancer. 2018;17(1):22.","journal-title":"Mol Cancer"},{"issue":"2","key":"3936_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1074\/mcp.M115.052423","volume":"15","author":"K Demeure","year":"2016","unstructured":"Demeure K, et al. Targeted proteomics to assess the response to anti-angiogenic treatment in human glioblastoma (GBM) *<sup><\/sup>. Mol Cell Proteomics. 2016;15(2):481\u201392.","journal-title":"Mol Cell Proteomics"},{"issue":"5","key":"3936_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/14728222.2018.1464141","volume":"22","author":"N Ludwig","year":"2018","unstructured":"Ludwig N, Whiteside TL. Potential roles of tumor-derived exosomes in angiogenesis. Expert Opin Ther Targets. 2018;22(5):409\u201317.","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"3936_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2217\/14796694.4.6.793","volume":"4","author":"SJ Lunt","year":"2008","unstructured":"Lunt SJ, et al. Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. Future Oncol. 2008;4(6):793\u2013802.","journal-title":"Future Oncol"},{"issue":"5","key":"3936_CR37","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ajpath.2017.01.010","volume":"187","author":"S Mahase","year":"2017","unstructured":"Mahase S, et al. Hypoxia-mediated mechanisms associated with antiangiogenic treatment resistance in glioblastomas. Am J Pathol. 2017;187(5):940\u201353.","journal-title":"Am J Pathol"},{"issue":"10","key":"3936_CR38","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"11","key":"3936_CR39","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963\u201372.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3936_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11910-013-0347-2","volume":"13","author":"OL Chinot","year":"2013","unstructured":"Chinot OL, et al. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep. 2013;13(5):347.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"3936_CR41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1472-6947-13-72","volume":"13","author":"D P\u00e9us","year":"2013","unstructured":"P\u00e9us D, Newcomb N, Hofer S. Appraisal of the Karnofsky performance status and proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak. 2013;13(1):72.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"3936_CR42","first-page":"86","volume":"1825","author":"A Jahangiri","year":"2012","unstructured":"Jahangiri A, Aghi MK. Biomarkers predicting tumor response and evasion to anti-angiogenic therapy. Biochim Biophys Acta. 2012;1825(1):86\u2013100.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"3936_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/sj.bjc.6605483","volume":"102","author":"N Murukesh","year":"2010","unstructured":"Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer. 2010;102(1):8\u201318.","journal-title":"Br J Cancer"},{"issue":"1","key":"3936_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","volume":"11","author":"TT Batchelor","year":"2007","unstructured":"Batchelor TT, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83\u201395.","journal-title":"Cancer Cell"},{"issue":"17","key":"3936_CR45","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","volume":"28","author":"TT Batchelor","year":"2010","unstructured":"Batchelor TT, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28(17):2817\u201323.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3936_CR46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11060-010-0390-7","volume":"103","author":"ER Gerstner","year":"2011","unstructured":"Gerstner ER, et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011;103(2):325\u201332.","journal-title":"J Neurooncol"},{"issue":"2","key":"3936_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1200\/JCO.2007.13.3652","volume":"26","author":"S Sathornsumetee","year":"2008","unstructured":"Sathornsumetee S, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26(2):271\u20138.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3936_CR48","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1172\/JCI125413","volume":"129","author":"H Yang","year":"2019","unstructured":"Yang H, et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest. 2019;129(10):4350\u201364.","journal-title":"J Clin Invest"},{"issue":"2","key":"3936_CR49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bbcan.2019.01.006","volume":"1871","author":"X Qin","year":"2019","unstructured":"Qin X, et al. The role of necroptosis in cancer: A double-edged sword? Biochim Biophys Acta Rev Cancer. 2019;1871(2):259\u201366.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6258","key":"3936_CR50","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1126\/science.aad0395","volume":"350","author":"N Yatim","year":"2015","unstructured":"Yatim N, et al. RIPK1 and NF-\u03baB signaling in dying cells determines cross-priming of CD8+ T cells. Science. 2015;350(6258):328\u201334.","journal-title":"Science"},{"key":"3936_CR51","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3389\/fimmu.2019.00651","volume":"10","author":"EJM Huijbers","year":"2019","unstructured":"Huijbers EJM, et al. Targeting tumor vascular CD99 inhibits tumor growth. Front Immunol. 2019;10:651\u2013651.","journal-title":"Front Immunol"},{"issue":"5","key":"3936_CR52","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3390\/ijms20051137","volume":"20","author":"LC Cardoso","year":"2019","unstructured":"Cardoso LC, et al. CD99 expression in glioblastoma molecular subtypes and role in migration and invasion. Int J Mol Sci. 2019;20(5):1137.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3936_CR53","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41467-018-05228-y","volume":"9","author":"J Ma","year":"2018","unstructured":"Ma J, et al. The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun. 2018;9(1):3292.","journal-title":"Nat Commun"},{"issue":"12","key":"3936_CR54","first-page":"1513","volume":"11","author":"EL Goode","year":"2002","unstructured":"Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1513\u201330.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"14","key":"3936_CR55","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1093\/hmg\/ddt131","volume":"22","author":"DN Church","year":"2013","unstructured":"Church DN, et al. DNA polymerase \u03b5 and \u03b4 exonuclease domain mutations in endometrial cancer. Hum Mol Genet. 2013;22(14):2820\u20138.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"3936_CR56","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ng.2503","volume":"45","author":"C Palles","year":"2013","unstructured":"Palles C, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45(2):136\u201344.","journal-title":"Nat Genet"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03936-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-03936-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03936-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T09:06:03Z","timestamp":1675501563000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-03936-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3936"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-03936-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"13 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of Asan Medical Center (IRB no. 2016-1245, 2017-0665, 2019-0082).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no potential competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}